CVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CVS Health Corp is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent settlement with the FTC reducing uncertainty make it an attractive long-term investment despite short-term technical weakness.
The MACD is negative and contracting, RSI is at 26.684 indicating oversold conditions, and moving averages are converging. The stock is trading near its support level of 70.821, suggesting limited downside risk. However, the short-term trend remains weak.
CVS has reached a settlement with the FTC over insulin pricing, which removes uncertainty and could enhance its reputation.
Analysts have upgraded the stock recently, with price targets suggesting significant upside.
Strong financial performance in Q4 2025, with revenue and net income showing robust growth.
Short-term technical indicators show weakness, with the stock trading below key resistance levels.
Concerns over Medicare Advantage payment rates and potential headwinds in
Gross margin has declined YoY, which could impact profitability.
In Q4 2025, CVS reported an 8.17% YoY increase in revenue, a 79.01% YoY increase in net income, and a 76.15% YoY increase in EPS. However, gross margin declined by -2.73% YoY.
Analysts are generally positive on CVS, with recent upgrades to 'Outperform' and price targets ranging from $90 to $98, indicating significant upside potential. The settlement with the FTC is seen as a positive development, reducing uncertainty in its pharmacy benefit management business.
